Across TCGA pan-cancer cohorts, ZNF682 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZNF682 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ZNF682 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF682 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, UCEC, and BLCA are the cancer types where ZNF682 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.242	0.745	.003	24	view →
UCEC	OS	Median	All	1.000	0.660	.023	14	view →
BLCA	DFS	Median	IV	0.135	0.471	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ZNF682 tumor-vs-normal RNA expression · all ZNF682 data types